A Phase III, Open-Label, Multicenter Randomized Study Evaluating Glofitamab as a Single Agent Versus Investigator's Choice in Patients With Relapsed/Refractory Mantle Cell Lymphoma

15755GO43878-NCT06084936OpenA Phase III, Open-Label, Multicenter Randomized Study Evaluating Glofitamab as a Single Agent Versus Investigator's Choice in Patients With Relapsed/Refractory Mantle Cell LymphomaGO43878NCT06084936IndustrialAdultTreatmentIIINon-Hodgkin LymphomaDunleavy, KieronGeorgetown University Medical Center : Ayodeji Olukoya; Lombardi Comprehensive Cancer Center : Ayodeji OlukoyaLymphomaOncology GroupLombardi Comprehensive Cancer Center (LCCC); Oncology PFS16185Ayodeji OlukoyaAyodeji Olukoyaaoo42@georgetown.edu2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>